A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of advanced neuroendocrine neoplasms in China
Shutong Liu, Yumeng Wang, Sen Hong, Lianru Zhang, Baorui Liu, Qin Liu · 2025
Read A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of advanced neuroendocrine neoplasms in China by Shutong Liu, Yumeng Wang, Sen Hong, Lianru Zhang, Baorui Liu, Qin Liu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12673297.txt.
Description
Shutong Liu and co-authors report, in a 2025 real-world study, how a drug called surufatinib performed against advanced neuroendocrine tumors in China. These tumors grow from hormone-making cells, and the drug blocks both blood vessel growth and immune escape routes. It is approved in China for tumors that cannot be cut out. The team reviewed twenty-one patients treated at one hospital over two years.
Disease was held in check in about four fifths of the patients, while tumors shrank clearly in a smaller share. Median time without growth reached 9.7 months. Patients with the related, more aggressive carcinoma form answered the drug at a higher rate than those with the standard tumor type, though the small numbers blur that gap. Serious side effects struck about a quarter of patients, and no one died from the treatment.
Catalog record
| CREATOR | Shutong Liu, Yumeng Wang, Sen Hong, Lianru Zhang, Baorui Liu, Qin Liu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |